KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome

European Respiratory Journal

Volumn 23, Issue 1, 2004, Pages 142-145

  Sato, H ^a   Callister, M E J ^a   Mumby, S ^a   Quinlan, G J ^a   Welsh, K I ^a   duBois, R M ^a   Evans, T W ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; KL 6; Mechanical ventilation

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN KL 6; MUCIN; UNCLASSIFIED DRUG;

ADULT; AIRWAY PRESSURE; ARTERIAL OXYGEN TENSION; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; MALE; OXYGENATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RESPIRATORY DISTRESS SYNDROME;

ADULT; ANTIGENS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; MUCINS; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0346505484     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00070303     Document Type: Article

References (14)

1. Ogawa Y, Ishikawa T, Ikeda K, et al. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res 2000; 6: 4069-4072.
2. Kohno N, Inoue Y, Hamada H, et al. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer Suppl 1994; 8: 81-83.
3. Takahashi T, Takamura K, Sakaue S, Ishii J, Yokouchi H, Nasuhara Y. Elevated serum KL-6 concentrations in patients with diabetes mellitus. J Diabetes Complications 2002; 16: 352-358.
4. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995; 108: 311-315.
5. Takahashi T, Munakata M, Suzuki I, Kawakami Y. Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 1998; 158: 1294-1298.
6. Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest 1996; 109: 1276-1282.
7. Hamada H, Kohno N, Akiyama M, Hiwada K. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest 1992; 101: 858-860.
8. Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993; 148: 637-642.
9. Kuwano K, Maeyama T, Inoshima I, et al. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases. Respirology 2002; 7: 15-21.
10. Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med 1997; 156: 109-115.
11. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute long injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342: 1301-1308.
12. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-824.
13. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-710.
14. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165: 378-381.